YILDIRIM, H. Ç. Et Al. 2022. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study. Breast , vol.66 , 85-88.

YILDIRIM, H. Ç., MUTLU, E., Chalabiyev, E., Özen, M., KESKİNKILIÇ, M., Ön, S., ... Çelebi, A.(2022). Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study. Breast , vol.66, 85-88.

YILDIRIM, HASAN Et Al. "Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study," Breast , vol.66, 85-88, 2022

YILDIRIM, HASAN Ç. Et Al. "Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study." Breast , vol.66, pp.85-88, 2022

YILDIRIM, H. Ç. Et Al. (2022) . "Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study." Breast , vol.66, pp.85-88.

@article{article, author={HASAN ÇAĞRI YILDIRIM Et Al. }, title={Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study}, journal={Breast}, year=2022, pages={85-88} }